Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330
Abstract APX3330 ((2E)‐2‐[(4,5‐dimethoxy‐2‐methyl‐3,6‐dioxo‐1,4‐cyclohexadien‐1‐yl)methylene]‐undecanoic acid), a selective inhibitor of APE1/Ref‐1, has been investigated in treatment of hepatitis, cancer, diabetic retinopathy, and macular edema. APX3330 is administered orally as a quinone but is ra...
Saved in:
Main Authors: | Larissa L. Silva (Author), Robert E. Stratford (Author), Richard Messmann (Author), Mark R. Kelley (Author), Sara K. Quinney (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
by: Hikari Araki, et al.
Published: (2022) -
Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
by: Soyoung Lee, et al.
Published: (2023) -
Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
by: Anu Shilpa Krishnatry, et al.
Published: (2021) -
Ascorbate Peroxidase Neofunctionalization at the Origin of APX-R and APX-L: Evidence from Basal Archaeplastida
by: Fernanda Lazzarotto, et al.
Published: (2021) -
Individualized Absorption Models in Population Pharmacokinetic Analyses
by: Mutaz M. Jaber, et al.
Published: (2020)